Women’s health biotech KaNDy dickering with Allergan about a $400M buyout deal — report

The latest buyout buzz focuses on a small UK biotech spinout working on a new drug for women’s health.

Bloomberg is reporting this morning that Allergan $AGN is in late-stage talks to buy out KaNDy Therapeutics in a deal that could value the company at up to $400 million.

Mary Kerr

Details are few and far between, but the company has a potential hormone replacement therapy called NT-814 that would fit the profile for Allergan’s BD team.

NeRRe Therapeutics, which spun out of GSK taking some unwanted programs in neurosciences, split off the women’s health biotech a few months ago.

KaNDy took a neurokinin-1,3 receptor antagonist — with potential as a hormone replacement therapy — with plans to take it into a Phase IIb study for postmenopausal vasomotor symptoms.

That would give Allergan some human data to look at as it beefs up that section of the pipeline, if a deal is completed.

KaNDy Therapeutics is led by managing director Mary Kerr and chaired by Iain Dukes, a venture partner at OrbiMed Advisors. The company is based at the Stevenage Bioscience Catalyst in the UK.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 29,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

RAPS Convergence 2018

Head of DMPK, Director
Magenta Therapeutics Cambridge, MA
Research Scientist - Disease Biology & Cellular Pharmacology
Recursion Pharmaceuticals Salt Lake City
Sr/Medical Director, Medical Affairs
A Rare Disease Biotech New Brunswick, NJ
VP, Pharmacovigilance
Aeglea BioTherapeutics Austin, TX
Process Scientist/Lead
Tmunity Therapeutics Philadelphia, PA

Visit Endpoints Careers ->